A new study has identified a network of genes that may underlie susceptibility to depression, anxiety, irritability, and neuroticism, providing fresh evidence that these psychiatric conditions share common genetic pathways. The research highlights the RBFOX1 gene as a key regulator of brain-related genetic networks and offers new insights that could support the development of more personalized treatments for mental health disorders.
The study, published in Progress in Neuro-Psychopharmacology and Biological Psychiatry, integrated data from genome-wide association studies (GWAS), predicted brain gene expression analyses, molecular network mapping, and rare disease research to identify genes associated with depression and at least one related psychological trait.
Researchers identified 19 genes that appear to contribute to the biological basis of depression and related psychiatric traits. Among them, RBFOX1 emerged as a master regulator that controls the activity of several genes involved in neuronal development, synaptic communication, and neurotransmission. The findings suggest that disruption of this regulatory network may alter multiple brain functions simultaneously, increasing vulnerability to several psychiatric disorders.
The analysis also identified SP4, TCF4, PAX6, and CADM2 as important components of the gene network. These genes have previously been associated with schizophrenia, insomnia, substance use disorders, and stress-related behavioral changes, indicating that diverse mental health conditions may share overlapping biological mechanisms.
According to the researchers, the findings reinforce the concept that depression is a polygenic disorder, arising from the combined effects of numerous genetic variants rather than a single genetic mutation. The inclusion of rare disease data further strengthened the evidence by identifying mutations with large biological effects that are linked to depression and anxiety.
The researchers believe that identifying shared genetic mechanisms could improve the prediction of disease risk, help classify patients based on their underlying biology, and accelerate the development of targeted therapies that address common molecular pathways across multiple psychiatric disorders.
The study also builds on previous research showing that RBFOX1 plays a critical role in brain development by regulating extensive gene networks. Variants in the gene have previously been associated with neurodevelopmental disorders, including autism spectrum disorder, intellectual disability, and epilepsy, underscoring its importance in normal brain function and neuropsychiatric disease.
While the findings provide important insights into the genetic architecture of depression and anxiety, the authors emphasize that further studies are needed to validate the results in larger and more diverse populations. Future research will also investigate sex-specific genetic differences, given the higher prevalence of depression among women, and examine how genes such as CADM2 contribute to the development of depression and related psychiatric disorders.
If confirmed, the findings could pave the way for more precise genetic risk assessment and personalized therapeutic strategies for individuals with depression, anxiety, and other closely related mental health conditions.
References
- Adel MR, Antón-Galindo E, Freudenberg F, Cormand B, Fernàndez-Castillo N. The RBFOX1 regulatory gene network contributes to major depressive disorder, anxiety, irritability and neuroticism. Prog Neuropsychopharmacol Biol Psychiatry. 2026;doi:10.1016/j.pnpbp.2026.111712.
- Bill BR, Lowe JK, DyBuncio CT, Fogel BL. Orchestration of neurodevelopmental programs by RBFOX1: implications for autism spectrum disorder. In: Rubenstein JLR, Christen Y, editors. Int Rev Neurobiol. 2013;113:251-67.